key: cord-0938685-1i57flmd authors: Christensen, Paul A.; Olsen, Randall J.; Long, S. Wesley; Snehal, Richard; Davis, James J.; Saavedra, Matthew Ojeda; Reppond, Kristina; Shyer, Madison N.; Cambric, Jessica; Gadd, Ryan; Thakur, Rashi M.; Batajoo, Akanksha; Mangham, Regan; Pena, Sindy; Trinh, Trina; Kinskey, Jacob C.; Williams, Guy; Olson, Robert; Gollihar, Jimmy; Musser, James M. title: Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas date: 2022-02-03 journal: Am J Pathol DOI: 10.1016/j.ajpath.2022.01.007 sha: 62571edbf1664da4e5e2e1eea1acac17dc7b5d76 doc_id: 938685 cord_uid: 1i57flmd Genetic variants of SARS-CoV-2 continue to dramatically alter the landscape of the COVID-19 pandemic. The recently described variant of concern designated Omicron (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of COVID-19 cases in many countries. Because Omicron was recognized very recently, many knowledge gaps exist about its epidemiology, clinical severity, and disease course. A genome sequencing study of SARS-CoV-2 in the Houston Methodist healthcare system identified 4,468 symptomatic patients with infections caused by Omicron from late November 2021 through January 5, 2022. Omicron very rapidly increased in only three weeks to cause 90% of all new COVID-19 cases, and at the end of the study period caused 98% of new cases. Compared to patients infected with either Alpha or Delta variants in our healthcare system, Omicron patients were significantly younger, had significantly increased vaccine breakthrough rates, and were significantly less likely to be hospitalized. Omicron patients required less intense respiratory support and had a shorter length of hospital stay, consistent with on average decreased disease severity. Two patients with Omicron “stealth” sublineage BA.2 also were identified. The data document the unusually rapid spread and increased occurrence of COVID-19 caused by the Omicron variant in metropolitan Houston, and address the lack of information about disease character among US patients. Over the last 14 months, the Alpha and Delta variants of concern (VOCs) of SARS-64 the most up-to-date data available for inclusion in this study. Because of the substantial 131 number of positive specimens obtained daily in the December 24, 2021 to December 132 29, 2021 period (sometimes exceeding 1,500) it wasn't possible to sequence most of 133 the samples collected during this period for inclusion in the study. 134 For analyses comparing features of patients infected with the Omicron VOC and 135 Alpha and Delta VOCs, all patients documented to be infected with these variants in the 136 Houston Methodist system were studied. The study included 40,991 unique patients 137 identified in this time frame for whom we had SARS-CoV-2 genome sequences. The We sequenced the SARS-CoV-2 genome of >90% of all positive cases in the Houston 165 Methodist healthcare system during the two sampling periods studied. Libraries for 166 whole SARS-CoV-2 genome sequencing were prepared according to version 4 167 (https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312, last 168 accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing protocol. The semi-169 automated workflow used has been described previously 2-6 . Sequence reads were 170 generated with an Illumina NovaSeq 6000 instrument. 171 Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service 172 Omicron increased in frequency unusually rapidly over a three-week period in 225 December (Figure 1, Figure 2) . By December 23, the genome sequence data showed 226 that Omicron accounted for >90% of all new COVID-19 cases in our healthcare system 227 There is a considerable lack of detailed information about patients with COVID-19 255 caused by the Omicron VOC, and data are especially lacking for US patients. We 256 compared available metadata for all Houston Methodist patients infected with Omicron, 257 Alpha, and Delta VOCs ( Table 1, Table 2 ). The populations differed significantly in 258 many characteristics, including median age, hospital admission rates, maximum 259 respiratory support, rate of vaccine breakthrough, and median length of stay ( Table 1 , 260 Table 2) . 261 Patients infected with Omicron were significantly younger than Alpha and Delta 262 patients ( Table 1, Table 2 ). Importantly, Omicron patients were hospitalized significantly 263 less frequently than patients infected with either the Alpha or Delta variants, and had a 264 significantly shorter median hospital length of stay ( Table 1, Table 2 ). 265 We next analyzed Omicron vaccine breakthrough cases ( Table 1, Table 2 ). We 266 found 2,497 of the 4,468 total Omicron patients (55.9%) for whom we have whole 267 genome sequence data met the CDC definition of vaccine breakthrough cases ( Table 1 , 268 Table 2 ). There was no simple relationship between the time elapsed since 269 administration of the second vaccination dose and the date of vaccination breakthrough. to 3.2% and 24.3% for Alpha and Delta VOCs, respectively) ( Table 1, Table 2 ). We Several questions arise from our findings, namely the underlying causes for the 340 differences we observe in Omicron compared to Alpha and Delta patients. Increased 341 vaccine breakthrough cases may be due to serologic and structural differences in 342 Omicron relative to Alpha and Delta. It is also possible that waning of immunity is a 343 contributing factor as well. We do not currently have serologic or other data that could 344 address this possibility in our patients. As noted above, ample in vitro and animal 345 infection model data have accumulated suggesting that Omicron is less virulent than 346 Delta or Alpha VOC. We speculate that the lower age of Omicron patients may be 347 attributable to a disproportionately greater likelihood of risky behaviors in the younger 348 population, for example less mask wearing and less social distancing. Regardless, 349 additional studies are required to gain more information about factors contributing to the 350 differences between Alpha, Delta, and Omicron patients that we identified in this study. 351 Because we sequence the genome of approximately 90% of SARS-CoV-2 352 causing COVID-19 in our diverse Houston Methodist patient population, and have done 353 so for almost two years, we are continuously monitoring the composition of this virus in 354 a major US metroplex. This affords us the opportunity to rapidly assess changes in 355 SARS-CoV-2 population genomic structure in the fourth largest city in the US. However, 356 our study has several limitations. Although we sequenced the genomes of SARS-CoV-2 357 causing 90% of all Houston Methodist COVID-19 cases in the study period, this sample 358 represents only approximately 5% of cases reported in the metropolitan region. Our 359 patient population will underrepresent some demographic groups, for example 360 homeless individuals and pediatric patients. The samples sequenced in this study were 361 obtained from symptomatic individuals, which means that it is possible that we failed to 362 identify Omicron subvariants or features preferentially represented in asymptomatic 363 individuals. It is likely that our study included some patients where Omicron was 364 detected on hospital admission but was incidental to the primary cause of admission. 365 The identification of two asymptomatic individuals with the Omicron "stealth" Genomic 409 characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi Molecular Architecture of Early 415 Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major 416 revealed by 8,857 genome sequences Severe Acute Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston Based on 12,476 Genome Sequences 454 Severity of Omicron variant of concern and vaccine effectiveness against symptomatic 455 disease: national cohort with nested test negative design study in Scotland Omicron spike mediated immune escape, infectivity and cell-cell fusion 464 Neutralization and Stability of SARS-CoV-2 Omicron Variant. bioRxiv 2021 Cicin-Sain L: Diminished 470 neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-471 based COVID-19 vaccinations. medRxiv 2021 Vlaemynck and previously infected individuals, the Netherlands Suthar MS: mRNA-1273 and BNT162b2 mRNA vaccines 483 have reduced neutralizing activity against the SARS-CoV-2 Omicron variant 486 Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection Omicron variant escapes neutralization by vaccinated and convalescent sera and 490 therapeutic monoclonal antibodies. medRxiv 2021 494 Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation 495 serum Striking Antibody Evasion Manifested 502 by the Omicron Variant of SARS-CoV-2 Considerable escape of SARS-CoV-2 variant Omicron to 509 antibody neutralization Effectiveness of COVID-19 vaccines against the Omicron 516 (B.1.1.529) variant of concern. medRxiv 2021 Reduced sensitivity 518 of SARS-CoV-2 Omicron variant to booster-enhanced neutralization Immunogenicity of convalescent and vaccinated sera against clinical 569 isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants Early estimates of SARS-CoV Omicron variant severity based on a matched cohort study, Ontario, Canada. medRxiv 573 2021 578 Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South SARS-CoV-2 variants of concern and variants under investigation in England 581 Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529) UK Health Security: UK Health Security 584 Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth 585 wave compared with previous waves in the Western Cape Province, South Africa. 586 medRxiv 2022 Penrice-Randal R, and Delta variants strains in a mouse model of severe COVID-19 The omicron (B.1.1.529) SARS-CoV-2 594 variant of concern does not readily infect Syrian hamsters. bioRxiv 2021 The SARS CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and 598 hamsters Nature Portfolio 2022 Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters Chan 607 JFW: The SARS-CoV-2 Omicron (B.1.1.529) variant exhibits altered pathogenicity, 608 transmissibility, and fitness in the golden Syrian hamster model SARS-CoV-2 variants of concern and variants under investigation in England period due to the massive number of daily positive specimens, as described in the 637 Materials and Methods section. C -F: Geospatial distribution of Omicron based on 638 home address zip code for each patient. C Note differences in heat map scale for each panel. Figures were generated using Tableau version 2021.2.7. (Tableau Software, LLC Non-Invasive Ventilation 63 (7.1%) 163 (9.5%) 226 (8.7%) Fisher's exact test Odds Ratio Vaccine Not Fully Vaccinated Fisher's exact test Odds Ratio: 38 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation Fisher's exact test Odds Ratio Vaccine No vaccine 1815 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay